NCT00047294View on ClinicalTrials.gov

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2001

Primary Completion Date

March 31, 2005

Study Completion Date

September 30, 2007

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

celecoxib

DRUG

temozolomide

DRUG

thalidomide

PROCEDURE

adjuvant therapy

Trial Locations (4)

22908

Cancer Center at the University of Virginia, Charlottesville

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00047294 - Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter